COX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 68, Issue 1, 2003, Pages 17-25

  Harding, Pamela ^a   Glass II, William F ^a   Scherer, Steven D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN TYPE II; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENALAPRIL; HYPERTROPHY; ISOENZYMES; KIDNEY DISEASES; MALE; NEPHRECTOMY; NITROBENZENES; ORGAN SIZE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SULFONAMIDES;

EID: 0037275780     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(02)00231-4     Document Type: Article

References (45)

1. L.A. Bruggeman, J.A. Pellicoro, E.A. Horigan, P.E. Klotman, Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression, Kidney Int. 43 (1993) 1219-1225.
2. A.M. Gallagher, H. Yu, M.P. Printz, Bradykinin-induced reductions in collagen gene expression involve prostacyclin, Hypertension 32 (1998) 84-88.
3. F. Pricci, G. Pugliese, P. Mene, G. Romeo, G. Romano, G. Galli, et al., Regulatory role of eicosanoids in extracellular matrix overproduction induced by long-term exposure to high glucose in cultured rat mesangial cells, Diabetologia 39 (9) (1996) 1055-1062.
4. D.L. Simmons, D.B. Levy, Y. Yannoni, R.L. Erikson, Identification of a phorbol ester-repressible v-src-inducible gene, Proc. Natl. Acad. Sci. USA 86 (1996) 1178-1182.
5. D.W. Coyne, M. Nickols, W. Bertrand, A.R. Morrison, Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids, Am. J. Physiol. 263 (1 Pt 2) (1992) F97-102.
6. A. Ristimaki, S. Garfinkel, J. Wessendorf, T. Maciag, T. Hla, et al., Induction of cyclooxygenase-2 by interleukin-1α, J. Biol. Chem. 269 (16) (1994) 11769-11775.
7. H. Inoue, C. Yokoyama, S. Hara, Y. Tone, Transcriptional regulation of human prostaglandin-endoperoxide-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells, J. Biol. Chem. 270 (1995) 24965-24971.
8. M.E. Hemler, W.E. Lands, Evidence of a peroxide-initiated free radical mechanism of prostaglandin biosynthesis, J. Biol. Chem. 255 (13) (1980) 6253-6261.
9. M. Schambelan, S. Blake, J. Sraer, M. Bens, M.P. Nivez, F. Wahbe, Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus, J. Clin. Invest. 75 (1985) 404-412.
10. H. Yanagisawa, J. Morrisey, A.R. Morrison, S. Klahr, Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction, Kidney Int. 37 (1990) 1528-1535.
11. E.A. Lianos, G.A. Andres, M.J. Dunn, Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic nephritis, J. Clin. Invest. 72 (1983) 1439-1448.
12. T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy, Proc. Natl. Acad. Sci. USA 90 (1993) 1814-1818.
13. J. Obata, T. Nakamura, H. Takano, A. Naito, H. Kimura, Y. Yoshida, et al., Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats, J. Hypertens. 18 (9) (2000) 1247-1255.
14. H. Kawaguchi, H. Saito, H. Yasuda, Renal prostaglandins and phospholipase A2 in spontaneously hypertensive rats, J. Hypertens. 5 (3) (1987) 299-304.
15. P.A. Craven, M.C. Patterson, F.R. DeRubertis, Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats, Diabetes 37 (4) (1988) 429-435.
16. C.S. Williams, R.N. DuBois, Prostaglandin endoperoxide synthase: why two isoforms?, Am. J. Physiol. 270 (1996) G393-G400.
17. P.E. Lipsky, P. Brooks, L.J. Crofford, R. DuBois, D. Graham, L.S. Simon, et al., Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease, Arch. Intern. Med. 160 (2000) 913-920.
18. S. Tomasoni, M. Noris, S. Zappella, E. Gotti, F. Casiraghi, S. Bonazzola, et al., Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J. Am. Soc. Nephrol. 9 (1998) 1202-1212.
19. J-L. Wang, H-F. Cheng, M-Z. Zhang, J. McKanna, R.C. Harris, Selective increase of cyclooxygenase-2 expression in a model of renal ablation, Am. J. Physiol. 275 (1998) F613-F622.
20. A. Hartner, M. Goppelt-Struebe, K.F. Hilgers, Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension, Hypertension 31 (1 Pt 2) (1998) 201-205.
21. S. Anderson, H.G. Rennke, B.M. Brenner, Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat, J. Clin. Invest. 77 (1986) 1993-2000.
22. R.L. Hall, W.L. Wilke, M.J. Fettman, Captopril slows the progression of chronic renal disease in partially nephrectomised rats, Toxicol. Appl. Pharmacol. 80 (1985) 517-526.
23. R.A. Preston, Renoprotective effects of antihypertensive drugs, Am. J. Hypertens, 12 (1 Pt 2) (1999) 19S-32S.
24. P. Harding, C. Stonier, G.M. Aber, Dose-dependent effects of angiotensin converting enzyme (ACE) inhibitors on glomerular prostanoid production by normotensive rats, Br. J. Pharmacol. 108 (1993) 327-330.
25. P. Harding, C. Stonier, G.M. Aber, Effect of angiotensin-converting enzyme inhibitors on glomerular eicosanoid production in normotensive and spontaneously hypertensive rats, Clin. Sci. 81 (4) (1991) 491-497.
26. H.F. Cheng, J.L. Wang, M.Z. Zhang, Y. Miyazaki, I. Ichikawa, J.A. McKanna, et al., Angiotensin II attenuates renal cortical cyclooxygenase-2 expression, J. Clin. Invest. 103 (1999) 953-961.
27. H. Geiger, W. Fierlbeck, M. Mai, M. Ruchti, H. Schonfeld, V. Dammrich, et al., Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR, Kidney Int. 51 (1997) 750-761.
28. J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W. Smith, et al., Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic, Proc. Natl. Acad. Sci. USA 91 (1994) 3228-3232.
29. R.J. Young, W.E. Hoy, P. Kincaid-Smith, A.E. Seymour, J.F. Bertram, Glomerular size and glomerulosclerosis in Australian Aborigines, Am. J. Kidney Dis. 36 (3) (2000) 481-489.
30. G.S. Lee, C.C. Nast, S.C. Peng, A. Artishevsky, C.G. Ihm, R. Guillermo, et al., Differential response of glomerular epithelial and mesangial cells after subtotal nephrectomy, Kidney Int. 53 (1998) 1389-1398.
31. P. Harding, O.A. Carretero, W.H. Beierwalters, Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics, J. Hypertens. 18 (2000) 1107-1113.
32. M.N. Muscara, N. Vergnolle, F. Lovern, C.R. Triggle, S.N. Elliott, S. Asfaha, et al., Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence, Br. J. Pharmacol. 129 (2000) 1423-1430.
33. J-L. Wang, H-F. Cheng, R.C. Harris, Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension, Hypertension 34 (1999) 86-101.
34. R.C. Harris, H-F. Cheng, J-L. Wang, M-Z. Zhang, J.A. McKanna, Interactions of the renin-angiotensin system and neuronal nitric oxide synthase in regulation of cyclooxygenase-2 in the macula densa, Acta. Physiol. Scand. 168 (2000) 47-51.
35. N. Perico, A. Remuuzi, F. Sangalli, N. Annollini, M. Mister, P. Ruggenenti, et al., The antiproteinuric effect of angiotensin antagonism in IgA nephropathy is potentiated by indomethacin, J. Am. Soc. Nephrol. 9 (1998) 2308-2317.
36. J-I. Wang, H-F. Cheng, S. Shappell, R.C. Harris, A selective COX-2 inhibitor decreases proteinuria and retards progressive renal injury in rats, Kidney Int. 57 (2000) 2334-2342.
37. G. Remuzzi, L. Imberti, M. Rossini, C. Morelli, C. Carminati, G.M. Cattaneo, et al., Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis, J. Clin. Invest. 75 (1985) 94-101.
38. V.E. Kelley, S. Sneve, S. Musinski, Increased renal thromboxane production in murine lupus nephritis, J. Clin. Invest. 77 (1986) 252-259.
39. Y. Yoshida, A. Fogo, I. Ischikawa, Effects of anti-hypertensive drugs on glomerular morphology: A close linkage between their anti-hypertrophic, anti-sclerotic action on remnant glomeruli. Kidney Int. 36 (1989) 626-635.
40. A. Fogo, E.P. Hawkins, A.D. Glick, P.L. Berry, M.L. Chiang, R.C. MacDonell, et al., Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis, Kidney Int. 38 (1990) 115-123.
41. M.M. Kett, D. Alcorn, J.F. Bertram, W.P. Anderson, Enalapril does not prevent renal arterial hypertrophy in spontaneously hypertensive rats, Hypertension 25 (1995) 335-342.
42. J.L. Logan, S.M. Lee, B. Benson, U.F. Michael, Inhibition of compensatory renal growth by indomethacin, Prostaglandins 31 (2) (1986) 253-261.
43. A. Hamaguchi, S. Kim, K. Ohta, K. Yagi, T. Yukimura, K. Miura, et al., Transforming growth factor beta-1 expression and phenotypic modulation in the kidney of hypertensive rats, Hypertension 26 (1) (1995) 199-207.
44. M. Naruse, S. Takagi, A. Tanabe, K. Naruse, C. Adachi, T. Yoshimoto, et al., Augmented expression of tissue endothelin-1 messenger RNA is a common feature in hypertensive rats, J. Cardivasc. Pharmacol. 36 (5 suppl 1) (2000) S195-197.
45. W. Weichert, A. Paliege, A.P. Provoost, S. Bachmann, Upregulation of juxtaglomerular NOS1 and COX-2 precedes glomerulosclerosis in fawn-hooded hypertensive rats, Am. J. Physiol. Renal Physiology 280 (2001) F706-F714.